JP2023538521A - キナーゼ阻害剤およびその使用 - Google Patents

キナーゼ阻害剤およびその使用 Download PDF

Info

Publication number
JP2023538521A
JP2023538521A JP2023507887A JP2023507887A JP2023538521A JP 2023538521 A JP2023538521 A JP 2023538521A JP 2023507887 A JP2023507887 A JP 2023507887A JP 2023507887 A JP2023507887 A JP 2023507887A JP 2023538521 A JP2023538521 A JP 2023538521A
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
pyrido
heterocyclyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023507887A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538521A5 (https=
Inventor
チェン チェン
Original Assignee
エイビーエム セラピューティックス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイビーエム セラピューティックス コーポレイション filed Critical エイビーエム セラピューティックス コーポレイション
Publication of JP2023538521A publication Critical patent/JP2023538521A/ja
Publication of JP2023538521A5 publication Critical patent/JP2023538521A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023507887A 2020-08-07 2021-08-06 キナーゼ阻害剤およびその使用 Pending JP2023538521A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063063113P 2020-08-07 2020-08-07
US63/063,113 2020-08-07
PCT/US2021/044907 WO2022032071A1 (en) 2020-08-07 2021-08-06 Kinase inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2023538521A true JP2023538521A (ja) 2023-09-08
JP2023538521A5 JP2023538521A5 (https=) 2024-08-15

Family

ID=77711412

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507887A Pending JP2023538521A (ja) 2020-08-07 2021-08-06 キナーゼ阻害剤およびその使用

Country Status (10)

Country Link
US (1) US20230303570A1 (https=)
EP (1) EP4192582A1 (https=)
JP (1) JP2023538521A (https=)
KR (1) KR20230112605A (https=)
CN (1) CN116710453A (https=)
AU (1) AU2021321536A1 (https=)
BR (1) BR112023002248A2 (https=)
CA (1) CA3179671A1 (https=)
MX (1) MX2023001312A (https=)
WO (1) WO2022032071A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4577546A1 (en) * 2022-08-25 2025-07-02 Enliven Inc. Naphthyridine compounds for inhibition of raf kinases
WO2024199388A1 (zh) * 2023-03-29 2024-10-03 微境生物医药科技(上海)有限公司 作为myt1抑制剂的化合物
WO2025064567A1 (en) * 2023-09-19 2025-03-27 Enliven Inc. Tricyclic phenols for inhibition of raf kinases
WO2025152919A1 (en) * 2024-01-15 2025-07-24 Impact Therapeutics (Shanghai) , Inc. Crystal forms of a weel inhibitor and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503802A (ja) * 2002-04-03 2006-02-02 エフ．ホフマン−ラ　ロシュ　アーゲー イミダゾ縮合化合物
JP2019520379A (ja) * 2016-07-01 2019-07-18 ジー１ セラピューティクス， インコーポレイテッド ピリミジン系の抗増殖剤
CN110950867A (zh) * 2018-09-27 2020-04-03 首药控股(北京)有限公司 一种fgfr4激酶抑制剂及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2348020A1 (en) 2009-12-23 2011-07-27 Esteve Química, S.A. Preparation process of erlotinib
FR2974088A1 (fr) * 2011-04-12 2012-10-19 Pf Medicament Composes pyrazolo[3,4-b]pyridines tri- et tetracycliques comme agent anticancereux
EP3684772B1 (en) * 2017-09-20 2023-12-06 ABM Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503802A (ja) * 2002-04-03 2006-02-02 エフ．ホフマン−ラ　ロシュ　アーゲー イミダゾ縮合化合物
JP2019520379A (ja) * 2016-07-01 2019-07-18 ジー１ セラピューティクス， インコーポレイテッド ピリミジン系の抗増殖剤
CN110950867A (zh) * 2018-09-27 2020-04-03 首药控股(北京)有限公司 一种fgfr4激酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
CA3179671A1 (en) 2022-02-10
KR20230112605A (ko) 2023-07-27
EP4192582A1 (en) 2023-06-14
CN116710453A (zh) 2023-09-05
WO2022032071A1 (en) 2022-02-10
MX2023001312A (es) 2023-04-12
AU2021321536A1 (en) 2023-03-09
US20230303570A1 (en) 2023-09-28
BR112023002248A2 (pt) 2023-03-07

Similar Documents

Publication Publication Date Title
KR101588583B1 (ko) 키나제 억제제로서의 이미다조트리아진 및 이미다조피리미딘
JP2023538521A (ja) キナーゼ阻害剤およびその使用
CN109400625B (zh) 稠合双环类化合物及其在药物中的应用
CN102665718B (zh) 可用作pdk1抑制剂的杂环化合物
WO2023045960A1 (zh) 一种吡啶类衍生物及其用途
CN106061976B (zh) 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
CN112384500B (zh) 免疫调节剂及其组合物和制备方法
KR102609431B1 (ko) Phd 저해제로서의 활성을 갖는 융합된 바이시클릭 헤테로아릴 유도체
CN111936475A (zh) 免疫调节剂及其组合物和制备方法
CN113072551B (zh) 含氮联苯类衍生物抑制剂、其制备方法和应用
JP2020525522A (ja) Ｒｈｏ−関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
TWI912419B (zh) 羥肟酸酯化合物、其製備方法及其應用
WO2019000682A1 (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
WO2019000683A1 (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
TWI693227B (zh) 新穎二環性或三環性雜環化合物
WO2022199662A1 (zh) 一种多环化合物及其应用
TW201706258A (zh) 作為ｔｎｆ信號傳遞調節劑之吲唑酮
EP3759106A1 (en) Oxadiazolylthiophene derivatives useful as histone deacetylase inhibitors
WO2025067126A1 (zh) 一种吡啶酮类化合物及其制备方法与应用
WO2023165581A1 (zh) 一种吡啶类衍生物及其用途
CN111747954B (zh) 吡嗪化合物和其用途
KR20250048005A (ko) 타이로신 키나제 2 저해제 및 이의 용도
WO2023125812A1 (zh) 取代的嘧啶酮衍生物、其药物组合物及医药上的用途
HK40100224A (zh) 激酶抑制剂及其用途
HK40127584A (zh) Pcsk9抑制剂及其使用方法

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240805

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240805

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250616

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250916

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251222